Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter studyTatsuya Ide, Takuji Torimura, Hironori Koga et al.|Hepatology International|2019Cited by 56
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019Masahito Nakano, Takuji Torimura, Shotaro Sakisaka et al.|Scientific Reports|2022Cited by 43
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching AnalysisTakashi Niizeki, Yasuhito Tanaka, Takayuki Tokunaga et al.|Targeted Oncology|2022Cited by 41
Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort studyMasahito Nakano, Takuji Torimura, Hironori Koga et al.|Cancer Medicine|2019Cited by 38
Trends in Hepatocellular Carcinoma Incidences in Japan Between 1996 and 2019Masahito Nakano, Takuji Torimura, Hiroshi Yatsuhashi et al.|Research Square|2021Cited by 1